BR112022021893A2 - Métodos e combinações para o tratamento de câncer utilizando anticorpos inibidores de ponto de verificação imune - Google Patents
Métodos e combinações para o tratamento de câncer utilizando anticorpos inibidores de ponto de verificação imuneInfo
- Publication number
- BR112022021893A2 BR112022021893A2 BR112022021893A BR112022021893A BR112022021893A2 BR 112022021893 A2 BR112022021893 A2 BR 112022021893A2 BR 112022021893 A BR112022021893 A BR 112022021893A BR 112022021893 A BR112022021893 A BR 112022021893A BR 112022021893 A2 BR112022021893 A2 BR 112022021893A2
- Authority
- BR
- Brazil
- Prior art keywords
- combinations
- methods
- cancer
- treatment
- immune checkpoint
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063023554P | 2020-05-12 | 2020-05-12 | |
| PCT/EP2021/062695 WO2021228978A1 (en) | 2020-05-12 | 2021-05-12 | Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022021893A2 true BR112022021893A2 (pt) | 2022-12-20 |
Family
ID=75977756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022021893A BR112022021893A2 (pt) | 2020-05-12 | 2021-05-12 | Métodos e combinações para o tratamento de câncer utilizando anticorpos inibidores de ponto de verificação imune |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20210355224A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4021940A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7387912B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230009354A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114729054A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2021269832B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022021893A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3158607A1 (cg-RX-API-DMAC7.html) |
| IL (3) | IL328607A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022006728A (cg-RX-API-DMAC7.html) |
| TW (2) | TWI870592B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021228978A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260077026A1 (en) * | 2022-09-07 | 2026-03-19 | The University Of Chicago | Methods for treating cancer with hyperactive adar enzymes |
| WO2025211692A1 (ko) * | 2024-04-02 | 2025-10-09 | (주)에트노바테라퓨틱스 | 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트 |
| TW202617179A (zh) * | 2024-06-13 | 2026-05-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗pd-l1抗體和抗ctla-4抗體聯合治療腫瘤 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US20040042972A1 (en) | 2002-04-11 | 2004-03-04 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for intranasal administration |
| WO2003087339A2 (en) | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for pulmonary administration |
| EP1494651A4 (en) | 2002-04-11 | 2010-10-13 | Medimmune Vaccines Inc | PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM |
| JP2006512102A (ja) | 2002-04-11 | 2006-04-13 | メディミューン・ヴァクシンズ・インコーポレーテッド | 噴霧乾燥による生物活性材料の防腐 |
| KR20050088175A (ko) | 2002-12-17 | 2005-09-02 | 메드이뮨 백신즈 인코포레이티드 | 생물활성 물질의 고압 분무 건조 |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| SG11201702401RA (en) * | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| US20180079814A1 (en) * | 2015-04-01 | 2018-03-22 | Medimmune Limited | Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer |
| JP7085709B2 (ja) * | 2016-06-20 | 2022-06-17 | エフ-スター セラピューティクス リミテッド | Pd-l1及びlag-3に結合する結合分子 |
| JP2019537619A (ja) * | 2016-09-27 | 2019-12-26 | オンコロジー、インコーポレイテッド | β2−糖タンパク質1のレベルに基づいて、バビツキシマブで癌を治療するための方法、およびそのためのアッセイ |
| KR20200020662A (ko) * | 2017-04-03 | 2020-02-26 | 온콜로지, 인크. | 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법 |
| AU2018273988C1 (en) * | 2017-05-26 | 2025-11-13 | Bruin Biosciences, Inc. | Chemoembolization agents |
| CN110914302A (zh) * | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| US20210260051A1 (en) * | 2018-06-14 | 2021-08-26 | Board Of Regents, The University Of Texas System | Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer |
| CA3102334A1 (en) * | 2018-06-15 | 2019-12-19 | Mina Therapeutics Limited | Combination therapies comprising c/ebp alpha sarna |
-
2021
- 2021-05-12 IL IL328607A patent/IL328607A/en unknown
- 2021-05-12 US US17/318,017 patent/US20210355224A1/en active Pending
- 2021-05-12 KR KR1020227024530A patent/KR20230009354A/ko not_active Ceased
- 2021-05-12 US US17/765,585 patent/US20220363762A1/en active Pending
- 2021-05-12 JP JP2022554243A patent/JP7387912B2/ja active Active
- 2021-05-12 MX MX2022006728A patent/MX2022006728A/es unknown
- 2021-05-12 TW TW110117153A patent/TWI870592B/zh active
- 2021-05-12 IL IL297640A patent/IL297640B1/en unknown
- 2021-05-12 TW TW114101922A patent/TW202535468A/zh unknown
- 2021-05-12 CN CN202180006543.2A patent/CN114729054A/zh active Pending
- 2021-05-12 CA CA3158607A patent/CA3158607A1/en active Pending
- 2021-05-12 CA CA3309448A patent/CA3309448A1/en active Pending
- 2021-05-12 WO PCT/EP2021/062695 patent/WO2021228978A1/en not_active Ceased
- 2021-05-12 BR BR112022021893A patent/BR112022021893A2/pt not_active Application Discontinuation
- 2021-05-12 EP EP21726376.3A patent/EP4021940A1/en active Pending
- 2021-05-12 AU AU2021269832A patent/AU2021269832B2/en active Active
- 2021-05-12 IL IL311936A patent/IL311936A/en unknown
-
2023
- 2023-11-09 JP JP2023191381A patent/JP2024016209A/ja active Pending
-
2024
- 2024-03-28 US US18/620,387 patent/US20240239893A1/en active Pending
- 2024-05-03 AU AU2024202963A patent/AU2024202963B2/en active Active
- 2024-11-28 AU AU2024266949A patent/AU2024266949A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230009354A (ko) | 2023-01-17 |
| TWI870592B (zh) | 2025-01-21 |
| AU2024202963A1 (en) | 2024-05-30 |
| IL297640A (en) | 2022-12-01 |
| IL297640B1 (en) | 2026-07-01 |
| WO2021228978A1 (en) | 2021-11-18 |
| US20210355224A1 (en) | 2021-11-18 |
| MX2022006728A (es) | 2022-06-09 |
| US20220363762A1 (en) | 2022-11-17 |
| JP2024016209A (ja) | 2024-02-06 |
| AU2024266949A1 (en) | 2024-12-19 |
| CA3158607A1 (en) | 2021-11-18 |
| AU2021269832A1 (en) | 2022-05-19 |
| TW202535468A (zh) | 2025-09-16 |
| CN114729054A (zh) | 2022-07-08 |
| TW202207976A (zh) | 2022-03-01 |
| IL311936A (en) | 2024-06-01 |
| AU2021269832B2 (en) | 2024-09-19 |
| EP4021940A1 (en) | 2022-07-06 |
| JP2023524359A (ja) | 2023-06-12 |
| JP7387912B2 (ja) | 2023-11-28 |
| AU2024202963B2 (en) | 2025-11-20 |
| US20240239893A1 (en) | 2024-07-18 |
| CA3309448A1 (en) | 2026-06-21 |
| IL328607A (en) | 2026-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200305A1 (ar) | أجسام مضادة لـ entpd2، توليفة علاجات، وطرق استخدام الأجسام المضادة وتوليفة العلاجات | |
| MX2020009037A (es) | Anticuerpos de b7-h4 y métodos para usarlos. | |
| MX2020008446A (es) | Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. | |
| CR20200467A (es) | Agentes anticuerpos anti-cd25 | |
| BR112014018481A2 (pt) | anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso | |
| MX2020012567A (es) | Anticuerpos anti-ox40 y metodos de uso. | |
| BR112016030686A2 (pt) | anticorpos anti tau humanizados | |
| CO2022001195A2 (es) | Anticuerpos dirigidos contra dll3 y usos de los mismos | |
| BR112017025080A2 (pt) | composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno | |
| BR112021008060A2 (pt) | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento | |
| BR112021016398A2 (pt) | Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer | |
| BR112022024084A2 (pt) | Receptores de antígeno quiméricos específicos para p95her2 e usos dos mesmos | |
| JOP20210169A1 (ar) | أجسام مضادة أحادية النسيلة ضد منطقة سلسلة بيتا من trbv9 بشري | |
| EP4644427A3 (en) | Manabodies and methods of using | |
| CL2023003047A1 (es) | Anticuerpo anti componente del complemento 1s (c1s) | |
| BR112022026533A2 (pt) | Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo | |
| EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
| MX2023008028A (es) | Anticuerpos anti-pd-l1 y proteinas de fusion de estos. | |
| MX2022006728A (es) | Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario. | |
| BR112019007147A2 (pt) | anticorpos anti-o1 e usos dos mesmos | |
| BR112023006989A2 (pt) | Anticorpos biespecíficos anti-pd-1/cd40 e usos dos mesmos | |
| DOP2025000290A (es) | Anticuerpos cd163 o proteínas de unión | |
| EA201990222A1 (ru) | Антитела к o2 и пути их применения | |
| BR112023014582A2 (pt) | Método de tratamento do câncer | |
| WO2022006219A3 (en) | Vhh polypeptides that bind to clostridium difficile toxin b and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122025009416-1 PROTOCOLO 870250038282 EM 12/05/2025 15:06. |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122026008272-7 PROTOCOLO 870260031914 EM 06/04/2026 16:59.O PEDIDO FOI DIVIDIDO NO BR122026008272-7 PROTOCOLO 870260031914 EM 06/04/2026 16:59. |